Valion Bio, Inc. (VBIO) Stock Ticker
Market factors today
Unlock the full VBIO picture
About Valion Bio, Inc.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
VBIO stock facts
| Ticker symbol | VBIO |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $12.5M |
| CEO | Michael R. Cavanaugh |
| Employees | 52 |
| Headquarters | San Antonio, TX, US |
| IPO date | 2021-11-11 |
| Website | valionbio.com |
What you can see for VBIO on Tickr
Live VBIO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the VBIO report.
Rankings
FAQ
What is the ticker symbol for Valion Bio, Inc.?
The ticker symbol for Valion Bio, Inc. is VBIO, listed on the NASDAQ.
What is VBIO?
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as…